GlassScriptPhysician profile
Joseph W Ray
NPI 1083960884
$642,183.92
in general payments reported to CMS, 2019-2025
18 companies · $190K in 2025
The $190K reported for 2025 was more than what 99% of Clinical Genetics (M.D.) providers received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $15K · 2021: $31K · 2022: $67K · 2023: $128K · 2024: $144K · 2025: $190K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300K · Consulting Fee: $79K · Travel and Lodging: $68K · Food and Beverage: $11K · Honoraria: $3,100 · Education: $820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300,064.00 |
| Consulting Fee | $79,405.00 |
| Travel and Lodging | $68,397.47 |
| Food and Beverage | $11,040.77 |
| Honoraria | $3,100.00 |
| Education | $819.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $403,305.92 | 2019-2025 | |
| Biomarin Pharmaceutical INC. | $115,753.39 | 2019-2025 | Palynziq, Voxzogo 1.2mg |
| Mirum Pharmaceuticals, INC. | $82,558.89 | 2024-2025 | Cholbam, Ctexli, Cholbam |
| Ptc Therapeutics, INC. | $16,468.80 | 2022-2025 | Emflaza, Sephience |
| Sarepta Therapeutics, INC. | $6,312.37 | 2022-2025 | Elevidys |
| Chiesi USA, INC. | $6,177.05 | 2020-2024 | Elfabrio |
| Travere Therapeutics, INC. | $5,346.19 | 2022-2023 | Cholbam |
| Amicus Therapeutics, INC. | $3,035.95 | 2023 | Galafold, Pombiliti, Opfolda |
| Itf Therapeutics LLC | $2,650.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $209.29 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $153.71 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $66.70 | 2019-2023 | Strensiq |
| Sanofi-Aventis U.S. LLC | $33.22 | 2019-2022 | |
| Cycle Pharmaceuticals INC | $26.27 | 2025 | Javygtor |
| Shire North American Group INC | $24.15 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi US Services INC. | $21.83 | 2025 | |
| Kyowa Kirin, INC. | $21.05 | 2025 | |
| Pharming Healthcare, INC. | $19.14 | 2024 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.